WO2001026588A2 - Methodes non invasives et avec effraction minimale et dispositifs pour le traitement de l'incontinence urinaire ou de l'obstruction urinaire - Google Patents

Methodes non invasives et avec effraction minimale et dispositifs pour le traitement de l'incontinence urinaire ou de l'obstruction urinaire Download PDF

Info

Publication number
WO2001026588A2
WO2001026588A2 PCT/US2000/015650 US0015650W WO0126588A2 WO 2001026588 A2 WO2001026588 A2 WO 2001026588A2 US 0015650 W US0015650 W US 0015650W WO 0126588 A2 WO0126588 A2 WO 0126588A2
Authority
WO
WIPO (PCT)
Prior art keywords
support
ofclaim
internal
urethra
urethral
Prior art date
Application number
PCT/US2000/015650
Other languages
English (en)
Other versions
WO2001026588A3 (fr
Inventor
Jeffrey E. Yeung
Teresa T. Yeung
Original Assignee
Yeung Jeffrey E
Yeung Teresa T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeung Jeffrey E, Yeung Teresa T filed Critical Yeung Jeffrey E
Priority to AU55983/00A priority Critical patent/AU5598300A/en
Publication of WO2001026588A2 publication Critical patent/WO2001026588A2/fr
Publication of WO2001026588A3 publication Critical patent/WO2001026588A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0004—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse
    • A61F2/0031—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra
    • A61F2/0036—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra implantable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008—Fixation appliances for connecting prostheses to the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008—Fixation appliances for connecting prostheses to the body
    • A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes

Definitions

  • This invention relates to methods and devices to treat urinary incontinence and obstruction in both men and women by non-invasive and/or minimally invasive methods and devices.
  • a device is inserted through the opening of the urethra and anchored in the mucosa to improve closure by supporting and strengthening the posterior wall of the urethra.
  • the bladder neck and/or urethra are partially ligated to decrease the lumen opening and improve closure capability.
  • a similar urethral insertion device can also stretch and stiffen the urethral wall against an obstruction to widen the lumen opening from within to promote urine flow.
  • Urinary incontinence is one of the most common urinary dysfunctions. The number of people living with urinary incontinence is far higher than estimated, even by most primary care physicians. A report published by the Agency for Health Care Policy and Research of the U.S. Public Health Service estimates that at least 10 million, more likely 20 million, adult Americans are affected by urinary incontinence. Many patients, especially women, do not mention their incontinence problems to their physicians. One of the reasons is that women are accustomed to using feminine hygiene products, some of which are designed for urine absorption. Among the elderly population, a 1975 report from the U.S. Department of Health showed that 55% of the surveyed patients living in long-term facilities had problems with urinary control.
  • Urinary incontinence is costly to patients and the health care systems. Annual sales of adult disposable diapers reach half of a billion dollars. The cost of medication and medical intervention for infections initiated and/or promoted by urinary incontinence is significant with no accurate estimates. In nursing homes alone, services incurred by incontinence are estimated to be $3 billion per year. The careers of the sufferers are often prematurely terminated or adversely affected by the offensive odor. The financial and social impact from urinary incontinence are very real, significant and rapidly growing with our aging population.
  • urethral sphincter The two major urinary closures in our bodies are the urethral sphincter and the bladder neck.
  • the term "urethral sphincter,” or “sphincter urethrae,” is often referred to as some sort of valve to stop the flow of urine.
  • the urethral sphincter cannot be identified with the naked eye, even under a microscope.
  • the interior layer of urethra is an integrated interaction between smooth and striated muscle with collagen and elastin forming spongy and supple mucosal folds, which drive the closure of the urethral lumen.
  • the exterior or outer layer of the urethra provides structural and ligament support.
  • a section of the urethral sphincter is depicted in Figure 1, with a longitudinal view shown in Figure 6.
  • the external striated layer of the urethral sphincter consists of bundles of circularly arranged fibers with maximal density at the mid-urethral level anteriorly, thinning laterally and becoming almost totally deficient posteriorly (Gosling J. A., et al., J. Anat. 129:216, 1979; Stanton S. L., et al., Surgery of Female Incontinence, 2nd Ed., Springer- Verlag, NY., 1986, pp. 4-5).
  • the slow-twitch muscle fibers primarily provide an involuntary urinary control; fast-twitch fibers are responsible for relaxation and voluntary sphincteric activity. Therefore, the sphincter is under partial voluntary control.
  • the female urethra is between 30 and 50 mm in total length, including the sphincteric length of about 28 mm, with the lumen diameter about 5.3 mm.
  • the sponge-like folding and suppleness of the resilient mucosa are promoted by sex hormone. With age and the decline of sex hormone, the mucosa at the middle and proximal portions of the urethra thins out (Stanton S. L., et al., Surgery of Female Incontinence, 2nd Ed., Springer-Verlag, NY., 1986, p. 5).
  • Bladder outlet resistance is a complex mechanism that involves the bladder neck, proximal urethral smooth muscle, anatomic support of the bladder base and urethra. Circular fibers of smooth muscle are found at the bladder neck. It seems that passive elastic tension is the most important factor leading to closure of the bladder neck and proximal urethra.
  • the bladder neck and the proximal urethra retain sphincteric function unless they are damaged by disease, surgery, pregnancy or by the slow pull of gravity on the muscular and ligamental supports (Campbell's Urology, Ed. P. Walsh et al, 7th Ed., Vol. 1, 1998, p.1007).
  • the structural (anatomic) support of the muscle-poor posterior urethral wall serves as a backboard against which the urethra is compressed during increased abdominal pressure.
  • Research studies using magnetic resonance imaging substantiate the importance of posterior support of the urethra.
  • the urethral lumen is actually pulled open as the posterior wall moves away from the anterior wall; then leakage occurs (Mostwin J. L. et al., Urol. Clin. North. Am. 1995, 22(3): 539-549; Campbell's Urology, Ed. P. Walsh et al, 7th Ed., Vol. 1, 1998, p. 1018).
  • sphincter abnormalities are most commonly caused by anatomic disruption after prostate surgery, trauma or neurologic abnormalities. After radical prostatectomy, five to ten percent of the patients suffer from permanent urinary incontinence.
  • sphincter abnormalities may be classified in two ways: (1) urethral hypermobility, and (2) intrinsic sphincter deficiency.
  • Urethral hypermobility is often caused by a weakness of pelvic floor support. During an increase in abdominal pressure, vesical (bladder) neck and proximal urethra rotationally descend and slip away from the supporting tissue behind. (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, pp.1011-1012).
  • Incontinence that occurs during stress is not always caused by the lack of anatomic support or sphincter abnormalities.
  • the stress initiates an abdominal detrusor contraction. This condition has been called stress hyper-reflexia. Stress incontinence and hyper-reflexia are easily differentiated. If the leakage stops as soon as the stress is over, it is stress incontinence. If voiding uncontrollably follows the stress, it is hyper-reflexia or detrusor hyperactivity, a common cause especially among the elderly (Campbell's Urology, Ed. P. Walsh et al, 7th Ed., Vol. 1, 1998, p.l023; Raz p. 231).
  • urethral hypermobility To determine urethral hypermobility, a cotton-swab test is used in physical examination. A well-lubricated and sterile cotton-swab is inserted into the urethra. During coughing, an unstable urethra sways and is evident by the outer portion of the cotton swab. If the sway is greater than 15 degrees, the patient has urethral hypermobility. Cystometry is one of the methods of urodynamics used to measure intravesical bladder pressure during the course of bladder filling.
  • the filling medium may be carbon dioxide or liquid, such as water, saline or radiographic contrast material. Pressure is measured during and after filling (Campbell's Urology, Ed. P.
  • Type 0 Patient complains of stress urinary incontinence. Videourodynamic test reveals that both vesical neck and proximal urethra are closed at rest and situated at or above the lower end of the pubis symphysis. During stress, the vesical neck and proximal urethra descend and open, assuming an anatomic configuration similar to that seen in types I and II stress urinary incontinence, but no urine leaks.
  • Type I The vesical neck is also closed at rest and situated above the inferior margin of the pubis symphysis.
  • Type IIA The vesical neck is also closed at rest and situated above the inferior margin of the pubis symphysis. During stress, the vesical neck and proximal urethra are also open, but with a rotational descent characteristic of a cystourethrocele (prolapse of bladder and urethra) which accompanies urine leakage.
  • Type IIB The vesical neck is closed at rest but situated at or below the inferior margin of the pubis symphysis.
  • Type III The bladder neck and urethra are open at rest indicating intrinsic sphincter dysfunction with or without hypermobility. Obvious urinary leakage associated with minimal abdominal pressure or gravity (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, pp.1013- 1016; Raz S., Female Urology, 2nd Ed., W.B. Saunders Co., 1996, p.345).
  • Non-surgical treatments include (1) pelvic floor exercise to strengthen pelvic muscles, (2) estrogen to thicken mucosa, (3) biofeedback and/or electrical stimulation to stimulate certain sets of urethral muscles, (4) ⁇ dpha-sympathomimetic drugs for intrinsic sphincter deficiency, and (5) mechanical devices to clamp the urethra.
  • Pelvic floor exercise and estrogen may have value as preventive measures. Biofeedback and electrical stimulation have been reported to cause improvement in 30% to 75% of patients; but "cure" is about 10% with few long-term data confirming the claims. Drug therapy has very limited success with significant side effects.
  • Urethral removable plugs (US patent 5,562,599 to Beyschlag, US patent 4,457,299 to Cornwell, US patent 5,131,906 to Chen, US patent 5,906,575 to Conway et al., US patent 5,885,204 to Vergano) are uncomfortable and troublesome to use, with increased possibility of urinary tract infections.
  • Penile clamping devices (US patent 4,942,886 to Timmons) are also highly uncomfortable, unnatural and may even cut off blood supply.
  • pessary devices (US patent 5,007,894 to Enhorning, US patent 5,386,836 to Biswas, US patent 5,785,640 to Kresch et al.) are designed to be worn in the vagina to compress and stop the leakage of urine. To be effective, the compression has to be strong and uncomfortable. Similar to the urethral plugs, pessary devices are troublesome to use, messy during menstrual periods and increase the possibility of infections.
  • Surgical Treatment In general, surgical treatments for urinary incontinence are far more successful than existing non-surgical treatments, and are the only reasonable long-term solution thus far.
  • the primary goals of the surgical approaches for sphincteric incontinence are (1) to correct urethral hypermobility and the excessive anatomic descent of the bladder neck / urethra, and (2) to increase urethral resistance by improving urethral coaptation and compression for treating intrinsic sphincter dysfunction (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, p. 1018, p.1066).
  • Surgical procedures designed to meet these two simple goals differ in their suture material, placement, depth, distance from urethra and location of abdominal anchoring sites.
  • sutures are used to pull and lift the vaginal wall forward and upward along with the urethra and bladder neck.
  • the vaginal tissue serves as the supporting backboard for the urethra.
  • Sutures are then fastened onto abdominal tissue or the pubis symphysis.
  • the major differences between surgical procedures of this type are the location of incisions, vaginal suspension, transvaginal suspension, and requirement of tissue dissection. Burch and Marshal-Marchetti-Krantz procedures use the vaginal-abdominal approach requiring abdominal incisions; while Raz suspensions, Stamey needle and Gittes needle are the transvaginal suspension procedures. Some surgeons prefer opening both abdominal and vaginal cavities.
  • Common anatomic surgical complications include recurrent or persistent urinary incontinence, irritation, urinary retention, obstruction and/or persistent postoperative pain, which may be caused by urethral kinking, improper suture placement or improper tension.
  • Other complications such as wound infection, abscess formation, genitofemoral nerve entrapment, bladder leaks or urethral damages, are common occurrences as well (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, p.l 100).
  • the overall complication rate ranges from 3% to 32% (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, p.l 101).
  • vaginal posterior prolapses have been reported following anatomic correction (Langer R. et al., Obstet. Gynecol. 1988, 72:866-869; Wiskind A. K., et al., Am. J. Obstet. Gynecol., 1992: 167:399-405; CampbeU's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, p.l 101).
  • a less invasive sling needle (US patent 5,899,909 to Claren et al.) has been invented to treat female sphincteric deficiency.
  • Various sling materials including autologous, heterologous, or artificial materials, have been used.
  • One invention (US patent 5,934,283 to Willem et al.) utilizes non-suture material as a sling. 7
  • Common complications of the slings include sensations of inguinal pulling, potential erosion of the urethra, urinary retention, urethral obstruction and enterocele (posterior vaginal hernia). Most of these complications are once again due to improper tension of the suture or sling.
  • Injectable or bulking agents such as collagen, polytetrafluoroethylene (PTFE), autologous fat and silicone, are injected into the wall of the bladder neck or urethral mucosa to decrease the size of the lumen opening to provide a more manageable or controllable sphincter.
  • PTFE polytetrafluoroethylene
  • silicone silicone
  • an artificial sphincter is implanted beneath the bladder neck around the urethra, mechanically pinching or restricting the opening of the lumen.
  • Numerous artificial sphincters (US patent 5,893,826 to Salama, US patent 5,704,893 to Timm, US patent 5,562,598 to Whalen et al, US patent 5,097,848 to Schwarz, US patent 4,994,020 to Polyak, US patent 4,705,518 to Baker et al., US patent 4,632, 114 to Todd et al. and US patent 4,552,128 to Haber) are designed to restrict the urethra mechanically.
  • Implantation of an artificial sphincter is an invasive surgery.
  • an inflatable cuff is inserted around the bulbous urethra in the male or the bladder neck in the female.
  • the tubing, liquid reservoir and pumps are implanted in the abdomen. Hospital post-surgical care is around three days.
  • Post-surgical complications include hematoma, cuff erosion, tissue atrophy, early infection from surgical contamination, late infection from urinary tract origin and mechanical malfunction such as tube kinking or leaks (Carson C. C, Urol. Clin. North. Am., 1989, 16:139-147).
  • Tissue atrophy is a natural result of cuff compression over time, which is often followed by cuff erosion with symptoms of pain, swelling, infection and/or bloody discharge. Corifirrnation of erosion mandates cuff removal (Campbell's Urology, Ed. P. Walsh et al., 7th Ed., Vol. 1, 1998, p.l 131- 1132).
  • Urethral Obstruction One of the most common urinary dysfunctions among middle aged and elderly men is urethral obstruction; and the most common cause of the obstruction is lumen narrowing of the supple urethra by an enlarged prostate called benign prostatic hyperplasia (BPH).
  • BPH benign prostatic hyperplasia
  • Alpha-blockers such as phenoxybenzamine, prazosin, terazosin and doxazosin, are used to relax smooth muscles such as the one around the prostate, thus minimizing the restriction around the urethra.
  • alpha-blockers have the side effect of hypotension, characterized by dizziness.
  • Finasteride is the only drug with clinically acceptable tolerance. Androgen suppression causes a reduction in prostate volume, hence reducing the obstruction around the urethra.
  • the primary side effect to androgen suppression is impotence and decreased ejaculatory volume.
  • this invention also corrects urethral hypermobility by providing posterior support and treats intrinsic sphincter dysfunction by increasing urethral resistance.
  • an internal urethral support is inserted through and anchored within the urethra to promote urethral closure from inside of the urethra, non- invasively.
  • Another part of this invention restricts or partially ligates the openings of the bladder neck and/or urethra through a minimally invasive suturing technique.
  • a similar internal urethral support is used within the urethra to stretch, stiffen and widen the urethral lumen against the obstruction.
  • an internal urethral support can be made with resilient material capable of bending or folding.
  • one or more internal urethral support(s) is / are fitted into a delivery device to be delivered into the urethra.
  • the closed position of the internal urethral support can also be called the delivery position.
  • the internal urethral support is best deployed and opened in the urethra laterally. In the deployed position, the urethral support is in a stable and relaxed configuration.
  • the tension of the urethral wall is overcome by the stretching and straightening of the internal urethral support.
  • the urethra is laterally stretched from a round to an elliptical shape, bringing the anterior and posterior walls closer together. Because of the pre-disposed shape and pre-stretched urethra, the forces required by the urethropelvic ligament to close the lumen of the urethra become less demanding during abdominal stress, such as sneezing or coughing.
  • the internal urethral support is hidden and buried in the resiliently spongy and supple lining of the coaptated mucosa of the anterior and posterior urethral walls. Furthermore, since the deployed internal urethral support causes the urethral wall to be stretched and stiffened under its tension, the muscle-poor posterior wall is less likely to move away from the compression of the muscle-rich anterior urethral wall during stress.
  • the internal urethral support can be selectively deployed toward the posterior wall inside the urethra.
  • the deployed internal urethral support stretches, stiffens and may even flatten a section of the urethral posterior wall to keep it from retreating during stress.
  • the muscle-poor posterior wall essentially remains stationary relative to the muscle-rich anterior wall, allowing a firm anterior compression to seal the lumen and prevent leakage during stress.
  • urethral supports can be individually deployed into a section of urethra to pre-stretch and pre-dispose the urethral wall, and at the same time to support a greater section of urethral posterior wall from inside and thus greatly enhance sphincteric action. Since each internal urethral support operates independently, the normal movements of urethra, including its lengthwise compression and extension, crucial for voiding and urinary control, should not be interfered with by multiple internal urethral support deployments. Resting Sphincteric Closure by Internal Urethral Support as Urethral Anchors Some patients, including those with the Type III stress incontinence, suffer from an opened urethra at rest, with the possibility of constant leakage even without stress.
  • a sphincteric shaper made with a curved or shape memory rod anchored by two or more internal urethral supports is embedded in the outwardly sagging posterior urethral wall.
  • the shape memory rod resumes the pre-disposed curvature, pulling the posterior wall toward the anterior wall to narrow or close the lumen.
  • the detrusor muscle and voluntary urethral muscle shorten and widen the urethra to overcome the device-induced closure, similar to the voluntary opening of the urethra following injection with large amounts of bulking agents, such as collagen.
  • One or more magnets is / are mounted on an internal urethral support.
  • One magnetic internal urethral support is installed in the posterior urethral wall; and another magnetic internal urethral support is installed in the anterior urethral wall across from it.
  • the magnets are mounted within the mucosa, approximating the posterior and anterior walls and closing the lumen.
  • voluntary voiding the detrusor muscles and voluntary urethral muscles shorten and widen the urethra to overcome the magnetically induced closure.
  • the controlling motions of the urethral sphincter are (1) shortening and widening the lumen to void, and (2) extending and narrowing the lumen to interrupt.
  • a urethral extensor comprised of two internal urethral supports acting as urethral anchors linked by a connector is designed to mimic the extension of the urethra.
  • the internal urethral supports are spring loaded, designed to pull the two internal urethral supports apart within the urethra.
  • the urethra lengthens and the opening of the lumen is narrowed and restricted during resting.
  • the detrusor muscle and voluntary urethral muscle shorten and widen the urethra to overcome the device-induced closure.
  • the opened and closed positions of the internal urethral support can be controlled by spring, hinge or multiple resilient elements.
  • the opened position of the internal urethral support can also be called the deployed position. It may even be possible to insert a rigid internal urethral support in the urethra by manipulation into a deployed position within the urethra, without bending or folding the device.
  • the internal urethral support can be made with biodegradable material, modular components, flexible and/or rigid portions.
  • tissue ingrowth openings can be made in the internal urethral support device, especially around mucosal contacts.
  • the internal urethral support is inserted into the urethra non-invasively to pre- stretch the wall, pre-dispose the urethra, support and/or stiffen the posterior wall for closure.
  • slings, injectables and artificial sphincters are presently being used to increase urethral resistance.
  • Internal urethra supports can also be used in multiple variations to promote urethral closure non-invasively: (1) to connect with a shape memory element bringing the posterior wall forward, (2) to pull the urethral walls together by magnets, or (3) to lengthen the urethra and collapse the lumen by tensile forces.
  • Non-invasive procedures usually translate into significantly lower costs, much shorter recovery times, far fewer complications, and are much more suitable to elderly or weak patients.
  • these non-invasive inventions may apply to men, women, and childbearing women, with minimal to no lifestyle restrictions.
  • the partial bladder neck or partial urethral ligation procedure proposed in this invention is different.
  • the suture is used only to restrict the lumen opening and support the urethral wall by encircling and being tied around the bladder neck or urethra, without attaching to abdominal tissue. Therefore, the suture is under minimal tension and rubbing friction around the bladder neck or urethra.
  • a spacer shaped and sized to provide a manageable lumen opening is inserted from the urethra into the bladder. With the partially restricted urine passages, the patient requires less muscular movement and intensity to close the partially restricted lumen, resulting in improved urinary control.
  • Urethral stents the only non-invasive device, are used to open the restricted urethra around the benign prostatic hyperplasia.
  • epithelial tissues penetrate into the lumen of the stents, which then require removal.
  • the internal urethral supports mentioned thus far for urethral closure can additionally be used to open the restricted urethra. Utilizing different internal urethral support orientations within the obstructed urethra, the compressed urethral wall can be stretched and shaped by one or multiple internal urethral support(s) to dilate the lumen and increase urine flow.
  • Suture delivery needle 1 Suture delivery needle distal opening 2
  • IUS dehvery device insertion marker 120 Suture knot 121
  • Figure 1 depicts a section of a weU-supported urethra 101 with a thick layer of resiUent mucosa 113 and a lumen 100 opening.
  • Figure 2 shows the weU-supported urethra 101 under stress with the urethropelvic Ugament 102 puUing the lateral waUs 131 of the supple urethra 101 to pinch the lumen 100 shut.
  • Figure 3 indicates bladder 111 positions: a weU-supported position in dashed lines and a descended position with a widened bladder neck 112 in soUd lines.
  • Figure 4 depicts a section of poorly supported, leaning urethra 101.
  • Figure 5 shows a faUed attempt of lumen 100 closure and hypermobiUty of the poorly supported urethra 101 during stress.
  • Figure 6 depicts a longitudinal section of the urethra 101 with urethropelvic Ugaments located perpendicularly above and below the page.
  • Figure 7 indicates a longitudinal view of urine 117 leakage from a weakened or poorly supported urethral posterior waU 119 during stress.
  • Figure 8 shows a typical prior art surgical procedure for urinary incontinence, using sutures
  • Figure 9 depicts a section of the surgicaUy corrected urethra 101 with sutures 21 puUing the vaginal 114 tissue to support and gently compress the urethral posterior waU 119.
  • Figure 10 shows the lumen 100 closure of the surgicaUy corrected urethra 101 under stress with urethropelvic Ugaments 102 pulling the lateral walls 131 of the supported urethra 101.
  • Figure 11 shows an internal urethral support (IUS) 104 with a resiUent element 106, tissue- anchoring elements 105, and penetration stops 122.
  • IUS internal urethral support
  • Figure 12 depicts a resiUently bent internal urethral support 104, simUar to the one in Figure 11.
  • Figure 13 depicts an IUS deUvery device 107 marked with insertion markers 120 and orientation line 143 and loaded with a resiUently bent internal urethral support 104.
  • Figure 14 shows the insertion of the IUS deUvery device 107 and deployment of the internal urethral support 104 into the lumen 100 of the urethra 101.
  • Figure 15 depicts a deployed internal urethral support 104 resiUently straightened in the urethra 101, lateraUy extended to pre-dispose the shape and direction of the lumen 100 closure during stress.
  • Figure 16 indicates a section of the poorly supported urethra 101 with the resiUently straightened internal urethral support 104 pre-stretching and breaking the waU tension to predispose the shape and enhance lumen 100 closure.
  • Figure 17 shows the ease of lumen 100 closure during stress when assisted by the waU- tension breaking and shape altering internal urethral support 104 hidden in the spongy mucosa 113.
  • Figure 18 depicts another IUS deUvery device 107 with the deployment opening 110 off- centered for reaching a different quadrant of the urethra 101.
  • Figure 19 shows yet another IUS deUvery device 107 with the internal urethral support 104 slanted or positioned for deploying the internal urethral support 104 toward one side of the urethra 101.
  • Figure 20 indicates a cross-section of a urethra 101 with an internal urethral support 104 partiaUy embedded in the mucosa, stretching and stiffening the posterior waU 119.
  • Figure 21 shows two internal urethral supports 104 supporting and strengthening a section of the posterior waU 119, without interfering with the normal urethral movements of lengthwise compression and extension.
  • Figure 22 indicates a restored lumen 100 stress closure by creating a backboard with internal urethral supports 104, stretching and stiffening the posterior waU 119.
  • Figure 23 depicts a longitudinal view of a poorly supported urethra 101 with an internal urethral support 104 embedded in the spongy mucosa 113 of the posterior waU 119.
  • Figure 24 shows lumen 100 closure during stress with an internal urethral support 104 supporting the urethral posterior waU 119, the urethropelvic Ugaments pulling perpendicular to the page.
  • Figure 25 indicates a cross-section of urethra 101 with a thick layer of mucosa 113 and an open lumen 100.
  • Figure 26 shows a normal lumen 100 closure during stress, initiated by the puUing of urethropelvic Ugaments 102, with closure distances A and B.
  • Figure 27 depicts a cross-section of an inadequate lumen 100 closure of a poorly supported urethra 101 during stress, where the closure distance b of the posterior waU 119 is inadequate.
  • Figure 28 indicates a cross-section of a poorly supported urethra 101 with the lumen 100 pre-stretched and reshaped by an internal urethral support 104.
  • Figure 29 shows a similar view as Figure 28 during stress, with distance of closure indicated by A' for the anterior waU 118 and B' for the posterior wall 119.
  • Figure 30 depicts a poorly supported urethra 101 with the lumen 100 pre-stretched by an internal urethral support 104 at the posterior waU 119, providing a supportive structure for a backboard.
  • Figure 31 indicates the lumen 100 closure of Figure 30 during stress, with distance of closure indicated by A" for the anterior waU 118, and a very smaU B" for the posterior waU 119.
  • Figure 32 shows a possible connection of two or more internal urethral supports 104 by a connector 144, which aUows vertical movement and resiUent bending of individual internal urethral support 104.
  • Figure 33 depicts an internal urethral support 104 with a connection port 145.
  • Figure 34 depicts an internal urethral support 104 as in Figure 33 in a bent configuration.
  • Figure 35 introduces a sphincteric shaper 152 with internal urethral supports 104 linked by a curved elastic rod 146.
  • Figure 36 shows IUS separators 149, which restrict and divide the internal urethral supports 104 during loading into a deUvery device and deployment into the urethra.
  • Figure 37 depicts the lumen 100 closure by indenting the posterior waU 119 inward with the sphincteric shaper 152. The direction of indentation is indicated by the arrow.
  • Figure 38 shows a longitudinal view of the lumen 100 closure by the curvature of the embedded sphincteric shaper 152.
  • Figure 39 depicts a similar view as Figure 38 during voiding with detrusor contraction 147, indicated by the arrows, which shortens and widens the urethra 101.
  • Figure 40 shows a spring-loaded pair of internal urethral supports 104 in a urethral extensor 153 device, where the springs 142 are stretched under tension.
  • Figure 41 depicts a similar device as the one in Figure 40 with a pair of spring retainers 151 to keep the springs 142 under tension during implantation.
  • Figure 42 depicts two contracting springs 142 puUing two internal urethral supports 142 further apart.
  • Figure 43 shows the urethral extensor 153 with the spring retainers 151 inserted into a urethra 101.
  • Figure 44 depicts tensile stretching of the urethra 101 by the urethral extensor 153 to mimic normal urethral closure, indicated by lumen 100 closure in dashed lines.
  • Figure 45 shows a longitudinal view of a stretch-induced lumen 100 closure by the urethral extensor 153 device at rest.
  • Figure 46 depicts a deployed or opened position of another version of an internal urethral support 104, which extends by a spring 142.
  • Figure 47 shows a compressed or closed position of the internal urethral support 104 indicated in Figure 46.
  • Figure 48 depicts another type of internal urethral support 104 with locking hinge 125 in an opened or deployed position.
  • Figure 49 shows a partiaUy folded internal urethral support 104 for urethral insertion.
  • Figure 50 indicates an internal urethral support 104 with two resiUent elements 106 held by two end caps 148, in an opened or deployed position.
  • Figure 51 shows a compressed or closed configuration of the internal urethral support 104 shown in Figure 50.
  • Figure 52 depicts a rigid internal urethral support 104 with smooth contour for installation in urethra, and tissue ingrowth openings 123 for anchoring and prevention of migration.
  • Figure 53 depicts another type of internal urethral support 104 with multiple tissue anchoring elements 105 and a resiUent element 106, in an opened or deployed position.
  • Figure 54 shows a resiUently bent internal urethral support 104, similar to the one in Figure 53.
  • Figure 55 indicates an IUS deUvery device 107 loaded with an internal urethral support 104.
  • Figure 56 shows a surgical approach to narrowing the enlarged opening of the bladder neck 112 and to gently compress the urethral sphincter by a suture 21 sling.
  • Figure 57 indicates an endoscopic suture device 154 containing a suture deUvery needle 1, shape memory needle 7, and suture receiving needle 10.
  • Figure 58 depicts the deployed hook of the shape memory needle 7, bridging the gap between suture deUvery needle 1 and suture receiving needle 10.
  • Figure 59 shows a spacer 128 sized to provide a manageable opening for bladder neck and/or urethra during the partial Ugation procedure.
  • Figure 60 depicts an abdominal penetration of the suture device 154 straddling the bladder neck 112 with a spacer 128 inserted.
  • the shape memory needle 7 contains a flexible filament 22.
  • Figure 61 indicates the deployment of the shape memory needle 7 into the distal opening
  • Figure 62 shows the advancement of the filament 22 by pushing the filament 22 into the proximal opening of shape memory needle 7, exiting the proximal opening of the suture receiving needle 10.
  • Figure 63 depicts retraction of the resiUent hook of shape memory needle 7 back into the suture deUvery needle 1, leaving only the suture 21 behind the bladder neck 112.
  • Figure 64 shows the withdrawal of the suture device 154, suture deUvery needle 1 and suture receiving needle 10, leaving the suture 21 looped behind the bladder neck 112.
  • Figure 65 depicts lumen 100 restriction by a suture 21 tied with a knot pusher 21.
  • the spacer 128 in the bladder neck 112 prevents excessive closure, which could lead to urine retention.
  • Figure 66 shows a semi-rigid external support 127 advancing behind the bladder neck 112, by the connecting suture 21.
  • Figure 67 indicates a partial Ugation with the external support 127 tied behind the bladder neck 112, with a final lumen 100 opening sized by the withdrawn spacer.
  • Figure 68 depicts multiple partial Ugations along the urethra 101 and around the bladder neck 112 with the external supports 127 strengthening the posterior waU 119.
  • Figure 69A shows another version of spacer 128 with two sizes and shapes for maximizing the efficacy of partial Ugations.
  • Figure 69B indicates a spacer 128 with a large cylindrical distal end, speciaUy designed to partiaUy Ugate the lumen 100 in the bladder neck 112.
  • Figure 70 shows a spacer 128 connected to a bladder filling and pressure checking instrument.
  • Figure 71 indicates the combination of partial Ugation to limit the size of lumen 100 and multiple internal urethral supports 104 to support the urethra 101, without interfering with normal urethral movements.
  • Figure 72 depicts the compression of lateral urethral waUs 131, greatly restricting the lumen 100 opening by benign prostatic hyperplasia.
  • Figure 73 shows the lumen 100 enlarged by the deployed internal urethral supports 104, stretching and stiffening the urethral walls.
  • Figure 74 indicates another lumen 100 enlargement by the deployed internal urethral supports 104, pushing out the lateral urethral waUs 131 above and anterior 118 and posterior 119 walls below.
  • Figure 75 depicts a modular internal urethral support 104 with a resiUent element 106, a tissue anchoring element 105 and a tissue ingrowth opening 123, composed of multiple pieces.
  • Figure 76 shows a magnetic urethral closure device 156 made with a pair of magnetic internal urethral supports 104.
  • Figure 77 indicates the attractive forces of the magnets 155 drawing the pair of internal urethral supports 104 close to each other.
  • Figure 78 depicts a urethral lumen 100 closure activated by magnetic attraction from the magnetic urethral closure device 156.
  • Figure 79 shows the opening of the lumen 100 from detrusor contraction, indicated by arrows, overcoming the magnetic forces of the magnetic urethral closure device 156.
  • Figure 80 indicates three types of tissue anchoring elements, a tissue-penetrating spear, a tissue hook and a tissue ingrowth opening 123.
  • Figure 1 depicts a section of a weU- supported urethra 101 with a thick layer of resiUent mucosa 113 and a lumen 100 opening.
  • Figure 2 shows the weU-supported urethra 101 under stress with the urethropelvic Ugament 102 pulling the lateral walls 131 of the supple urethra 101 to pinch the lumen 100 shut.
  • the traditional prior art surgical treatment for urinary incontinence is to support the urethral posterior waU 119, usuaUy by repositioning the vagina 114 with sutures 21.
  • the vaginal repositioning in Figure 8 indicates the pre-surgical positions of the vagina 114 in dotted lines and the urethra 101 and bladder in dashed lines.
  • Figure 9 indicates the posterior waU 119 support in a section of the urethra 101.
  • This significantly invasive procedure provides the backboard support needed for the urethral sphincteric closure during stress as shown in Figure 10. Instead of invasively placing a support outside the urethra 101, the internal urethral support
  • IUS 104 is a non-invasive or micro-invasive insert, entering through the external opening of the urethra 101 to anchor within the urethra 101.
  • the internal urethral support 104 must be stiff enough to stretch out the urethral waU 131, anchor weU without shifting, be thin enough to aUow mucosal 113 coaptation, and be biocompatible with the urethra 101.
  • the internal urethral support 104 For constructing the internal urethral support 104, numerous materials, including plastics and metals, are adequately stiff to stretch the supple urethra 101, but not many can be bent from an open or deployed position as in Figure 1 1 to a closed or deUvery position as in Figure 12. Shape memory aUoys, such as nickel titanium, and some polymers, such as polypropylene, polyethylene and polytetrafluoroethylene, have the elastic modulus to tolerate bending as weU as the stiffness to perform. Other types of internal urethral supports 104, indicated in Figures 46 to 52, do not require such vigorous bending for deUvery.
  • the spring 142 loaded internal urethral support 104 can extend nearly twice the length from a deUvery position as indicated in Figure 47 to a deployed position in Figure 46.
  • the internal urethral support 104 can also be operated by a hinge 125 between two projecting members. In the deUvery position, the internal urethral support 104 is folded, as depicted in Figure 49. Within the urethra 101, the projecting member wiU then be deployed, as indicated in Figure 48. The deployed position can be locked by a locking hinge 125 to ensure proper anchoring within the urethra 101.
  • FIG. 11 depicts a longitudinal view of urethral stretching, shaping and/or widening by the deployed internal urethral support 104.
  • tissue ingrowth openings 123 as indicated in Figure 52 promote incorporation of tissue into the internal urethral support 104 to prevent device migration.
  • This style of internal urethral support 104 may be formed of a generally rigid material and manipulated into a deployed position within the urethra, without bending or folding the device. It is also possible to have both tissue ingrowth opening 123 and tissue anchoring elements 105 in an internal urethral support 104 as indicated in Figure 80.
  • Figure 53 shows variation of the internal urethral support 104 in a deployed position, Figure 54 in a deUvery position and Figure 55 within a deUvery device 107.
  • This version of the internal urethral support has a series of hook-like tissue anchoring elements 105 designed to anchor onto the mucosa 113.
  • the urethral 101 sphincter consists of bundles of circularly arranged muscular fibers with maximal density in the anterior section, thinning lateraUy and being almost totaUy deficient posteriorly. Research indicates that during stress on a poorly supported urethra 101 depicted in Figures 3 and 4, an unequal movement of the muscular anterior 118 and muscle deficient posterior 119 walls appears, resulting in retreat of the posterior waU 119, depicted in Figures 5. Thus, leakage occurs, as indicated in Figure 7.
  • the urethra 101 is pre-stretched lateraUy by the internal urethral support 104 along the direction of closure when stressed.
  • the deployed internal urethral support 104 serves two major functions, (1) breaking the tension of urethral waU for easy closure, as indicated in Figures 14 to 17, and/or (2) stiffening the urethral waU to prevent retreat.
  • Figure 13 shows a deUvery device 107 loaded with an internal urethral support 104 for urethral insertion.
  • Figure 14 shows the deUvery device 107 in the urethra 101.
  • a flexible tube 109 and a flexible plunger 108 are made to tolerate the curvature of the urethra 101 during insertion.
  • the insertion marker 120 located on the exterior of the deUvery device 107 aUows the surgeon to estimate the inserted depth of deUvery device 107.
  • the deUvery device 107 can be coated or made with echogenic material.
  • a radiopaque coating or material can be used.
  • an orientation line 143 is drawn on the device 107 to confirm the lateral position of the internal urethral support 104 prior to deployment.
  • the plunger 108 pushes the resiUently closed internal urethral support 104 out of the deploy opening 110, projecting both ends of the internal urethral support 104 outward into the mucosal 113 waU as indicated in Figure 15.
  • a centered deploy opening 110 at the distal end as shown in Figure 13 provides deployment of the internal urethral support 104 near the center of the urethra 101, pre-stretching the lateral waU 131 as indicated in Figures 15 and 16.
  • the lumen 100 is more compliant to close or collapse by the tensile contraction of the urethropelvic Ugament 102 during stress, as depicted in Figure 17.
  • the thin resiUent element 106 of the internal urethral support 104 is concealed by the coaptation of the soft and spongy mucosa 113, the interior layer of urethra 101.
  • the deploy opening 110 can be shifted from the center to the side of the distal end as shown in Figure 18.
  • the internal urethral support 104 can be placed at an angle in the deUvery device 107 as indicated in Figure 19.
  • Figure 20 depicts a deployed internal urethral support 104 stretching and supporting the posterior waU 119 with the resiUent element 106 mostly hidden or buried in the spongy mucosa 113.
  • FIG. 23 shows the longitudinal view of the internal urethral support 104 supporting the posterior waU 119.
  • the lumen 100 is prepared for closure during stress as indicated in Figure 22, reducing the retreat and hypermobiUty of the posterior waU 119.
  • Figure 24 shows the longitudinal view of the lumen 100 stress closure, due to the urethropelvic Ugaments 102 (shown in Figure 22) puUing perpendicularly above and below the page, with the backboard supporting internal urethral support 104 embedded in the posterior waU 119.
  • FIG. 25 A cross-sectional view of a normal lumen 100 opening is depicted in Figure 25.
  • the lumen 100 is closed by the tensUe forces of the urethropelvic Ugament 102.
  • the urethropelvic tensile forces 102 are transmitted into urethral waU closure forces pulling the anterior waU 118 through distance A, and the posterior waU 119 through distance B for a successful lumen 100 closure.
  • the urethropelvic tensile forces 102 are not weU transmitted into closure forces for the posterior waU 119, which puUs only a smaU distance b. As a result, leakage occurs.
  • Figure 28 depicts a poorly supported urethra 101 pre-stretched and pre-shaped by an internal urethral support 104 at the center, breaking lateral 131 waU tension, and at the same time increasing anterior 118 and posterior 119 waU tension.
  • the internal urethral support 104 is pre-shaping or reshaping the cross-section of the urethra 101.
  • the lumen 100 in Figure 29 is closed more easily with shorter waU closure distances than even a normal urethral lumen 100 as in Figure 26, where A' ⁇ A for anterior 118 closure and B' ⁇ B for posterior 119 closure.
  • Figure 30 depicts an internal urethral support 104 embedded in and firmly supporting and stretching the posterior waU 119 of a poorly supported urethra 101.
  • the posterior waU 119 remains almost stationary, where B" is very smaU, holding almost stiU for the coaptation of the muscle-rich anterior waU 118, and the tensile puUing of the urethropelvic Ugament 102.
  • biodegradable internal urethral supports 104 are non-invasive and temporary in patients. In feet, it can be helpful as a diagnostic tool to determine the cause of incontinence, optimize the position of the permanent internal urethral support 104, and to maximize the success rate of traditional treatments, aU with rninimal invasiveness.
  • the internal urethral support 104 can also be assembled from modular components, as indicated in Figure 75.
  • nickel-titanium chosen for either super-elastic or shape memory properties can be used in the resilient section 106 in connection with polypropylene or other polymers for the penetration stops 122 contacting the mucosa 113.
  • TerminaUy sterilizing the internal urethral support 104 and deUvery device 107 with autoclave, gamma, E-beam or other sterilizing technique can prevent possible urethral infection.
  • Polymers such as polyetheretherketone, polysulfone, polyethylene, polypropylene, polycarbonate, polyurethane, polyvinyl chloride, polyimide, delrin polytetrafluoroethylene or others, can tolerate one or more of the sterilization techniques.
  • the internal urethral support 104 can also be coated or blended with lubricants, biocompatible material, anticorrosive, antibiotics, growth factors, hormones, time-release substances, radiopaque, echogenic, radioactive, plasma, tissue sealing, hydrophiUc, hydrophobic material or a drug.
  • the internal urethral support 104 can be removed by cutting with endoscopic scissors and retrieving with forceps if necessary for reasons such as infection, discomfort, ineffectiveness or others. It is also possible to design a removable internal urethral support 104 without cutting.
  • two internal urethral supports 104 may be linked by a connector 144, as depicted in Figure 32, which aUows vertical movement to accommodate the natural mobiUty of the urethra 101.
  • the connector 144 utilizes a post capable of sUding in a tube.
  • the internal urethral support 104 can also have a connecting port 145 as indicated in Figure 33 for linking with other devices, without interfering with the bending capabiUty, as shown in Figure 34.
  • the present invention provides a non-invasive alternative, a sphincteric shaper 152 containing a shape memory or elastic rod 146, which can be inserted near the posterior urethral waU 119 and anchored by internal urethral supports 104 as indicated in Figure 37.
  • the shape memory rod 146, three anchoring internal urethral supports 104 and two round end caps 148 to avoid urethral puncture are shown in Figure 35.
  • IUS separators 149 are inserted as indicated in Figure 36.
  • the IUS separators 149 can be made with biodegradable materials, such as PLA or PGA, or with moisture activated disintegrating materials, such as gelatin or collagen.
  • the anchored shape memory or elastic rod 146 resumes the pre-disposed curvature, puUing the posterior 119 waU forward to meet the anterior 118 waU, thus narrowing and closing part of the lumen 100 as shown in Figure 37.
  • Figure 38 depicts a longitudinal view of the shape memory induced lumen 100 closure, created by the inwardly indented posterior waU 119 embedded with the internal urethral support 104 anchored elastic rod 146.
  • both detrusor 147 and urethral muscles contract to increase urethral wall tension, shortening and widening the lumen 100, and overcoming the indented distance created by the shape memory rod 146 as indicated in Figure 39.
  • the lumen 100 opens and urine 117 flows.
  • a similar mechanism for lumen opening is observed in a urethra injected with as much as 30 cc or more of bulking agents, such as collagen.
  • the connection port 145 of the internal urethral support 104 is square, as indicated in Figure 33; and, as shown in Figure 35, the shape memory rod 146 is also square. Turning of the shape memory rod 146 in the urethra 101 would decrease the lumen 100 closure capabiUty.
  • Figure 76 and Figure 77 show the magnetic urethral closure device 156 made with a pair of magnetic internal urethral supports 104 shown apart and magneticaUy drawn together, respectively.
  • the urethral walls are stretched from within, elongating the cross-section of the urethra 101, placing the posterior 119 and anterior 118 walls even closer to each other, and enhancing the magnetic effect of the device.
  • the detrusor muscle and voluntary urethral muscle shorten and widen the urethra 101 to overcome the magneticaUy induced closure, as indicated in Figure 79.
  • a corrosive resistant coating such as polytetrafluoroethylene or other material, can be appUed.
  • the urethral extensor 153 disclosed herein contains two anchored internal urethral supports 104 mounted within an open urethral sphincter.
  • the two internal urethral supports 104 are under tension to separate from each other, thus pulling and extending the urethra 101 to narrow and close the lumen 100.
  • Figure 40 shows two spring 142 loaded internal urethral supports 104, where the tensile forces are indicated by the arrows.
  • Spring retainers 151 are used to keep the springs 142 and the internal urethral supports 104 under tension as depicted in Figure 41 ; and the whole spring loaded device is instaUed in the urethra 101 as indicated in Figure 43.
  • the spring retainers 151 can be made with biodegradable materials, such as PLA or PGA, or with moisture activated disintegrating materials, such as gelatin or collagen. After degradation or disintegration of the spring retainers 151, the two internal urethral supports 104 are puUed apart by the springs 142, as indicated in Figure 42. With the device in the urethra
  • Figure 45 depicts a longitudinal view of the extension-induced lumen 100 closure with a thin connector 144, in this case a square rod, concealed in the coaptation of mucosa 113.
  • the sling procedure is designed to loop a suture 21, tissue or other material behind the bladder neck 112 or urethra 101 to gently compress and restrict the outlet.
  • Figure 56 depicts the sling correction from a pre-surgical position in dashed line to a manageable opening at the bladder neck 112.
  • the most arduous part of placing an artificial sphincter or a sling is the dissection behind the bladder neck 112 or urethra 101.
  • the vaginal 114 cavity is frequently cut opened for suture 21 passage.
  • the endoscopic suture device 154 in US Patent 5,895,395, which is hereby incorporated by reference, may be helpful to place a suture 21 through a smaU abdominal incision and around the bladder neck 112 without dissecting around the bladder neck 112 or cutting the vagina 114.
  • Figures 57-64 show the operation of the endoscopic suture device 154, which can be used to improve the sling procedure (prior art) of Figure 56 and/or the partial Ugation procedure of Figures 65-68.
  • Major components of the suture device 154 contain three needles operating between two simple needle positions.
  • a hoUow shape memory needle 7 with a sharp hook is resiUently straightened in a suture deUvery needle 1.
  • the hook is deployed from the suture deUvery needle 1 into a suture retrieving needle 10.
  • the procedure begins with the insertion of a spacer 128 as indicated in Figure 59, through the urethra 101 into the bladder 111. A smaU abdominal incision is made.
  • the suture device 154 is guided by an endoscope to penetrate the Ugament and to straddle the bladder neck 112 or urethra 101 with the suture deUvery needle 1 and suture retrieving needle 10.
  • the suture deUvery needle 1 and suture retrieving needle 10 can also be inserted separately and independently.
  • a flexible filament 22 connecting tip-to-tip with a suture 21 is threaded through the proximal opening of the shape memory needle 7 to the distal opening, as shown in Figure 60.
  • the resiUent hook of the shape memory needle 7 is then deployed from the suture deUvery needle 1, penetrating tissue behind the bladder neck 112 or urethra 101 into the suture retrieving needle 10, as depicted in Figure 61.
  • the suture-connecting filament 22 is pushed from the proximal opening of the shape memory needle 7 into the distal opening 11 of the suture retrieving needle 10, as indicated in Figure 62.
  • the suture-connecting filament 22 continues to advance and is retrieved from the proximal opening of the suture retrieving needle 10. As a result, the mid-portion of the suture 21 loops around the bladder neck 112 and both ends of the suture 21 are exposed outside the incision. The filament 22 is then cut off from the suture 21. The hook is retracted back into the suture deUvery needle 1, leaving only the suture 21 looped behind the bladder neck 112, as shown in Figure 63. Then, the suture device 154 is withdrawn, as depicted in Figure 64. The suture 21 is tied down to the spacer 128 inside the bladder neck 112 with a knot pusher 26, as shown in Figure 65.
  • the urethra 101 may benefit greatly from a firm posterior support, while the bladder neck 112 may gain the most resistance simply by a Ughtly restricting suture 21 to narrow the funneled outlet intensified by anatomic descent.
  • a semi-rigid external urethral support 127 can be linked, guided and tied behind the urethra 101 or bladder neck 112 by the suture 21, as depicted in Figure 66.
  • the bladder neck 112 is partiaUy Ugated, restricting the lumen 100 opening by suture 21, without attaching to the abdominal waU.
  • the distal portion of the spacer 128 can be made cylindrical, with diameter between 3 mm to 10 mm, for the bladder neck 112, foUowed by a flat section 133 at the posterior surface of the spacer 128, as indicated in Figure 69 A, to conform to the external urethral support 127 shaping the urethra 101.
  • an orientation line 130 visible to the surgeon is marked on the spacer 128.
  • markers 129 are visible to assist with the insertion procedure.
  • an inflatable baUoon at the distal end of the spacer 128 anchoring in the bladder can be helpful (not shown).
  • the distal portion of the spacer 128 is the operative area for partial Ugation.
  • the operative area is made pinch resistant to ensure proper Ugated lumen size.
  • the non-operative part of the spacer 128 is preferred to be flexible.
  • the sutures 21 can be sewn onto the Ugaments without the possibiUty of sUding along the urethra 101. Since the partial Ugations work independently, the normal urethral vertical movement, for urinary voiding and interruption, should not be interfered with, as shown in Figure 68 with arrows indicating the mobiUty of the urethra 101.
  • the suture 21 can be replaced with another tying element, such as a band or a piece of tissue, to increase the width of partial Ugation.
  • the tying element can be tied or fastened with a locking device, rather than a knot pusher.
  • a bladder filling medium 135 and pressure checking instrument 138 connected to the spacer 128, as indicated in Figure 70.
  • the bladder 111 is fiUed with a medium 135, such as colored saline, through the spacer 128 to about 20 to 50 cm water pressure, usuaUy less than 300 cc.
  • the spacer 128 is then withdrawn from the urethra 101. If the type of anesthesia does not interfere with the involuntary control of the bladder 111 and urethral sphincter, no medium 135 leakage indicates a good chance of success with the partial Ugations. If leakage appears, more or tighter Ugations with a thinner spacer 128 would be beneficial, while the patient is stiU under anesthesia.
  • SimUar methods using partial Ugation and a spacer 128 device can be used in supporting and fortifying around the exterior blood vessel waU of an aneurysm. Unlike current treatments using co Us or stents to fill inside the baUooning aneurysm, partial Ugation with a suture 21 or other material supports the exterior waU without constant blood contact, no device migration within the blood vessel, no blood clotting from coil or stent and no migratable blood clot which can cause strokes or other serious ailments. Partial Ugation and/or the spacer 128 device can also be used to restrict the opening of the pylorus to delay stomach emptying for weight loss purposes.
  • partial Ugation of the pylorus is likely to be much less invasive than the stomach stapling technique currently being used to treat obesity. Furthermore, the partial Ugation method is likely to be totaUy reversible by cutting a suture or a pylorus restricting material.
  • urinary incontinence is the result of at least one, most likely multiple malfunctions in the urinary system
  • treating urinary incontinence may take more than one approach.
  • using the combination of partial Ugation to restrict the lumen 100 and reverse the funneling effect of the bladder neck 112, and the internal urethral support 104 to pre-stretch, pre-shape and support the urethral walls for stress closure may provide a highly effective result, as indicated in Figure 71.
  • the devices in this invention are designed to work independently and cooperatively with each other and with other treatments as weU.
  • the hoUow and compliant urethra 101 is not made to resist external compression by surrounding tissue ingrowth, such as benign prostatic hyperplasia (BPH).
  • BPH benign prostatic hyperplasia
  • the lumen 100 opening shrinks, as depicted in Figure 72. Prostate growth is sex hormone dependent. For some patients, the growth leads to urethral obstruction.
  • the internal urethral support 104 can stretch open the urethral waU from within, relocating the surrounding prostatic tissues.
  • the internal urethral support 104 can be selectively deployed to press against an obstructive tissue.
  • Figure 73 shows two sets of internal urethral supports 104, above and below, stretching the anterior 118 and posterior 119 walls, and at the same time adding stiffness to the lateral 131 urethral waUs. As a result, the lumen 100 opening is widened to expedite urine flow.
  • Figure 74 depicts two sets of staggering internal urethral supports 104, above and below, but rotated ninety degrees from each other, alternating the stretching and stiffening of anterior 118, posterior 119 and lateral 131 walls, to ensure the widening of the lumen 100 along the obstructed urethra 101.
  • the urethral widening may be equaUy effective with a single internal urethral support 104 within a section of urethra 101, rather than using a pair or more of internal urethral supports 104.
  • opening of urethral obstructions with the non-invasive internal urethral support 104 may provide long-lasting clearance within the urethra 101.
  • the device can be more generaUy caUed an internal lumen support. Similar methods and devices used in opening the urinary tract with the internal lumen support can be modified in size and shape to open and support a section of coUapsed or clotted blood vessels. EspeciaUy for vessels too smaU for stent, bypass or angioplasty, a simple, smaU and flexible internal lumen support can adequately open coUapsed sections or kinks in blood vessels. Medical Alert Tags Most of the devices in this invention are designed to increase urethral resistance by narrowing the lumen 100.
  • catheters In hospitals, health care professionals often insert catheters into the urethra 101 for draining. It is possible that the insertion of catheters, especiaUy 12 French or larger, can dislocate the device or even injure the urethra 101. If the patient has the device, a medical alert tag should be worn.

Abstract

Pour traiter l'incontinence urinaire, on insère de manière non-invasive un support urétéral interne dans l'ouverture de l'urètre et on l'ancre dans la muqueuse élastique pour améliorer la fermeture du sphincter pendant l'effort, en soutenant et en renforçant l'urètre, en particulier sa paroi postérieure. Pour traiter les sphincters qui restent ouverts même au repos, on utilise également le support urétéral interne de l'invention comme ancre urétérale interne sur laquelle se monte un élément à mémoire de forme, un aimant ou un extenseur, pour fermer ledit sphincter. En chirurgie avec effraction minimale, on ligature partiellement le col vésical et/ou l'urètre pour restreindre l'ouverture de la lumière et pour améliorer la capacité de fermeture. La lumière réduite est dimensionnée de manière reproductible et est limitée par un élément d'écartement inséré dans l'urètre. Pour ce qui concerne l'obstruction urétérale, on peut également utiliser des dispositifs d'insertion urétéraux similaires pour étirer et raidir la paroi de l'urètre contre une obstruction, élargir ainsi l'ouverture de la lumière de l'intérieur et favoriser l'écoulement de l'urine.
PCT/US2000/015650 1999-10-13 2000-06-07 Methodes non invasives et avec effraction minimale et dispositifs pour le traitement de l'incontinence urinaire ou de l'obstruction urinaire WO2001026588A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55983/00A AU5598300A (en) 1999-10-13 2000-06-07 Non-invasive and minimally invasive methods and devices for treating urinary incontinence or obstruction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15933899P 1999-10-13 1999-10-13
US60/159,338 1999-10-13
US17047599P 1999-12-13 1999-12-13
US60/170,475 1999-12-13

Publications (2)

Publication Number Publication Date
WO2001026588A2 true WO2001026588A2 (fr) 2001-04-19
WO2001026588A3 WO2001026588A3 (fr) 2001-10-11

Family

ID=26855861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015650 WO2001026588A2 (fr) 1999-10-13 2000-06-07 Methodes non invasives et avec effraction minimale et dispositifs pour le traitement de l'incontinence urinaire ou de l'obstruction urinaire

Country Status (2)

Country Link
AU (1) AU5598300A (fr)
WO (1) WO2001026588A2 (fr)

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032321A1 (fr) * 2000-10-19 2002-04-25 Yeung Jeffrey E Dispositif de fermeture sphincterienne micro-invasive commande par les muscles uretraux
EP1238638A1 (fr) * 2001-03-08 2002-09-11 Tokin Corporation Sphincter artificiel
WO2002080821A1 (fr) * 2001-04-06 2002-10-17 Core Medical, Inc. Appareil et procedes de fermeture d'ouvertures dans les disques intervertebraux
EP1517726A2 (fr) * 2002-07-02 2005-03-30 The Foundry, Inc. Procedes et dispositifs pour le renforcement de lumieres corporelles et des sphincters
EP1887976A2 (fr) * 2005-05-20 2008-02-20 Neotract, Inc. Dispositifs, systemes et procedes de traitement de l'hyperplasie prostatique benigne et d'autres troubles
US7737109B2 (en) 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US7736388B2 (en) 1999-04-09 2010-06-15 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US7753933B2 (en) 2000-12-14 2010-07-13 Ensure Medical, Inc. Plug with detachable guidewire element and methods for use
US7753923B2 (en) 1999-04-09 2010-07-13 Evalve, Inc. Leaflet suturing
US7766926B2 (en) 2002-04-30 2010-08-03 Vance Products Incorporated Sling for supporting tissue
US7942806B2 (en) * 2005-12-29 2011-05-17 Ethicon, Inc. Stress urinary incontinence implant and device for deploying same
US7981123B2 (en) 1997-09-12 2011-07-19 Evalve, Inc. Surgical device for connecting soft tissue
US7981139B2 (en) 2002-03-01 2011-07-19 Evalve, Inc Suture anchors and methods of use
US8029518B2 (en) 1999-04-09 2011-10-04 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
US8057510B2 (en) 2000-12-14 2011-11-15 Ensure Medical, Inc. Plug with collet and apparatus and method for delivering such plugs
US8075587B2 (en) 2000-12-14 2011-12-13 Ensure Medical, Inc. Apparatus and methods for sealing vascular punctures
US8088144B2 (en) 2005-05-04 2012-01-03 Ensure Medical, Inc. Locator and closure device and method of use
US8123703B2 (en) 1999-04-09 2012-02-28 Evalve, Inc. Steerable access sheath and methods of use
US8177795B2 (en) 2008-10-21 2012-05-15 Cayenne Medical, Inc. Meniscal repair systems and methods
US8216256B2 (en) 1999-04-09 2012-07-10 Evalve, Inc. Detachment mechanism for implantable fixation devices
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US8343174B2 (en) 1999-04-09 2013-01-01 Evalve, Inc. Locking mechanisms for fixation devices and methods of engaging tissue
US20130025604A1 (en) * 2006-12-21 2013-01-31 Oz Harmanli Vaginal pessary
US8579934B2 (en) 2003-10-17 2013-11-12 Ensure Medical, Inc. Locator and delivery device and method of use
US8753359B2 (en) 2008-02-18 2014-06-17 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US8814885B2 (en) 2008-03-04 2014-08-26 Cayenne Medical, Inc. Arthroscopic meniscal repair systems and methods
US8852229B2 (en) 2003-10-17 2014-10-07 Cordis Corporation Locator and closure device and method of use
US8888811B2 (en) 2008-10-20 2014-11-18 Covidien Lp Device and method for attaching an implant to biological tissue
US8906045B2 (en) 2009-08-17 2014-12-09 Covidien Lp Articulating patch deployment device and method of use
US8926654B2 (en) 2005-05-04 2015-01-06 Cordis Corporation Locator and closure device and method of use
US8940001B2 (en) 2005-05-20 2015-01-27 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US8945152B2 (en) 2005-05-20 2015-02-03 Neotract, Inc. Multi-actuating trigger anchor delivery system
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
WO2015193890A1 (fr) * 2014-06-16 2015-12-23 Novogi Ltd. Appareil et procédé pour anastomose par compression étagée
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US9486208B2 (en) 2009-05-01 2016-11-08 Cayenne Medical, Inc. Meniscal repair systems and methods
US9492148B2 (en) 2000-12-14 2016-11-15 CARDINAL HEALTH SWITZERLAND 515 GmbH Apparatus and methods for sealing vascular punctures
US9655602B2 (en) 2000-12-14 2017-05-23 CARDINAL HEALTH SWITZERLAND 515 GmbH Vascular plug having composite construction
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
CN108025180A (zh) * 2015-08-12 2018-05-11 英诺威讯有限公司 用于括约肌和其它组织再生的系统
US9999424B2 (en) 2009-08-17 2018-06-19 Covidien Lp Means and method for reversibly connecting an implant to a deployment device
US10130353B2 (en) 2012-06-29 2018-11-20 Neotract, Inc. Flexible system for delivering an anchor
US10159554B2 (en) 2008-02-18 2018-12-25 Covidien Lp Clip for implant deployment device
US10182898B2 (en) 2008-02-18 2019-01-22 Covidien Lp Clip for implant deployment device
US10188392B2 (en) 2014-12-19 2019-01-29 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
US10195014B2 (en) 2005-05-20 2019-02-05 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10238494B2 (en) 2015-06-29 2019-03-26 Evalve, Inc. Self-aligning radiopaque ring
US10238495B2 (en) 2015-10-09 2019-03-26 Evalve, Inc. Delivery catheter handle and methods of use
US10265061B2 (en) 2005-05-20 2019-04-23 Neotract, Inc. Latching anchor device
US10292801B2 (en) 2012-03-29 2019-05-21 Neotract, Inc. System for delivering anchors for treating incontinence
US10299780B2 (en) 2005-05-20 2019-05-28 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US10314586B2 (en) 2016-12-13 2019-06-11 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
US10349932B2 (en) 2013-03-15 2019-07-16 Neotract, Inc. Anchor delivery system
US10363138B2 (en) 2016-11-09 2019-07-30 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10376673B2 (en) 2015-06-19 2019-08-13 Evalve, Inc. Catheter guiding system and methods
US10390943B2 (en) 2014-03-17 2019-08-27 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
US10398553B2 (en) 2016-11-11 2019-09-03 Evalve, Inc. Opposing disk device for grasping cardiac valve tissue
US10413408B2 (en) 2015-08-06 2019-09-17 Evalve, Inc. Delivery catheter systems, methods, and devices
US10426616B2 (en) 2016-11-17 2019-10-01 Evalve, Inc. Cardiac implant delivery system
US10426509B2 (en) 2005-05-20 2019-10-01 Neotract, Inc. Median lobe destruction apparatus and method
US10492792B2 (en) 2005-05-20 2019-12-03 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
US10631871B2 (en) 2003-05-19 2020-04-28 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
US10736632B2 (en) 2016-07-06 2020-08-11 Evalve, Inc. Methods and devices for valve clip excision
US10743876B2 (en) 2011-09-13 2020-08-18 Abbott Cardiovascular Systems Inc. System for fixation of leaflets of a heart valve
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US10925587B2 (en) 2005-05-20 2021-02-23 Neotract, Inc. Anchor delivery system
US11065119B2 (en) 2017-05-12 2021-07-20 Evalve, Inc. Long arm valve repair clip
US11298115B2 (en) 2020-08-03 2022-04-12 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions
US11304715B2 (en) 2004-09-27 2022-04-19 Evalve, Inc. Methods and devices for tissue grasping and assessment
US11653947B2 (en) 2016-10-05 2023-05-23 Evalve, Inc. Cardiac valve cutting device
US11672520B2 (en) 2017-12-23 2023-06-13 Teleflex Life Sciences Limited Expandable tissue engagement apparatus and method
US11744726B2 (en) 2013-08-01 2023-09-05 Cook Medical Technologies Llc Tissue adjustment implant
US11957358B2 (en) 2020-09-21 2024-04-16 Evalve, Inc. Adjustable arm device for grasping tissues

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425535B2 (en) 2005-05-20 2013-04-23 Neotract, Inc. Multi-actuating trigger anchor delivery system
US9301826B2 (en) 2008-02-18 2016-04-05 Covidien Lp Lock bar spring and clip for implant deployment device
US9161749B2 (en) 2011-04-14 2015-10-20 Neotract, Inc. Method and apparatus for treating sexual dysfunction

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2297031A1 (fr) * 1975-01-07 1976-08-06 Rhone Poulenc Ind Dispositif d'obturation
US4091807A (en) * 1976-11-04 1978-05-30 Dickinson Ben Wade O Iii Intra-vaginal device and method of use
US4632114A (en) * 1985-03-22 1986-12-30 C. R. Bard, Inc. Urethral sphincter cuff
EP0498912A1 (fr) * 1989-02-10 1992-08-19 Goran E. Enhorning Appareil pour contrôler l'incontinence chez la femme
EP0778011A2 (fr) * 1995-12-07 1997-06-11 Arterial Vascular Engineering, Inc. Stent pour déploiement transluminal
US5860425A (en) * 1991-12-03 1999-01-19 Boston Scientific Technology, Inc. Bladder neck suspension procedure
US5865715A (en) * 1998-01-20 1999-02-02 Wallick; H. David Contraction resistance vaginal muscle exerciser
US5888188A (en) * 1995-06-29 1999-03-30 Fundacao E. J. Zerbini Mechanical sphincter for controlling urinary incontinence
US5895395A (en) * 1997-07-17 1999-04-20 Yeung; Teresa T. Partial to full thickness suture device & method for endoscopic surgeries
US5921995A (en) * 1996-10-16 1999-07-13 Nitinol Medical Technologies, Inc. Anastomosis Device

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2297031A1 (fr) * 1975-01-07 1976-08-06 Rhone Poulenc Ind Dispositif d'obturation
US4091807A (en) * 1976-11-04 1978-05-30 Dickinson Ben Wade O Iii Intra-vaginal device and method of use
US4632114A (en) * 1985-03-22 1986-12-30 C. R. Bard, Inc. Urethral sphincter cuff
EP0498912A1 (fr) * 1989-02-10 1992-08-19 Goran E. Enhorning Appareil pour contrôler l'incontinence chez la femme
US5860425A (en) * 1991-12-03 1999-01-19 Boston Scientific Technology, Inc. Bladder neck suspension procedure
US5888188A (en) * 1995-06-29 1999-03-30 Fundacao E. J. Zerbini Mechanical sphincter for controlling urinary incontinence
EP0778011A2 (fr) * 1995-12-07 1997-06-11 Arterial Vascular Engineering, Inc. Stent pour déploiement transluminal
US5921995A (en) * 1996-10-16 1999-07-13 Nitinol Medical Technologies, Inc. Anastomosis Device
US5895395A (en) * 1997-07-17 1999-04-20 Yeung; Teresa T. Partial to full thickness suture device & method for endoscopic surgeries
US5865715A (en) * 1998-01-20 1999-02-02 Wallick; H. David Contraction resistance vaginal muscle exerciser

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8740918B2 (en) 1997-09-12 2014-06-03 Evalve, Inc. Surgical device for connecting soft tissue
US9510837B2 (en) 1997-09-12 2016-12-06 Evalve, Inc. Surgical device for connecting soft tissue
US7981123B2 (en) 1997-09-12 2011-07-19 Evalve, Inc. Surgical device for connecting soft tissue
US7736388B2 (en) 1999-04-09 2010-06-15 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8740920B2 (en) 1999-04-09 2014-06-03 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8057493B2 (en) 1999-04-09 2011-11-15 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8343174B2 (en) 1999-04-09 2013-01-01 Evalve, Inc. Locking mechanisms for fixation devices and methods of engaging tissue
US8123703B2 (en) 1999-04-09 2012-02-28 Evalve, Inc. Steerable access sheath and methods of use
US9510829B2 (en) 1999-04-09 2016-12-06 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8500761B2 (en) 1999-04-09 2013-08-06 Abbott Vascular Fixation devices, systems and methods for engaging tissue
US7753923B2 (en) 1999-04-09 2010-07-13 Evalve, Inc. Leaflet suturing
US8216256B2 (en) 1999-04-09 2012-07-10 Evalve, Inc. Detachment mechanism for implantable fixation devices
US8187299B2 (en) 1999-04-09 2012-05-29 Evalve, Inc. Methods and apparatus for cardiac valve repair
US8409273B2 (en) 1999-04-09 2013-04-02 Abbott Vascular Inc Multi-catheter steerable guiding system and methods of use
US9044246B2 (en) 1999-04-09 2015-06-02 Abbott Vascular Inc. Methods and devices for capturing and fixing leaflets in valve repair
US8029518B2 (en) 1999-04-09 2011-10-04 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US8734505B2 (en) 1999-04-09 2014-05-27 Evalve, Inc. Methods and apparatus for cardiac valve repair
US7737109B2 (en) 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
WO2002032321A1 (fr) * 2000-10-19 2002-04-25 Yeung Jeffrey E Dispositif de fermeture sphincterienne micro-invasive commande par les muscles uretraux
US7753933B2 (en) 2000-12-14 2010-07-13 Ensure Medical, Inc. Plug with detachable guidewire element and methods for use
US8409248B2 (en) 2000-12-14 2013-04-02 Core Medical, Inc. Plug with detachable guidewire element and methods for use
US8075587B2 (en) 2000-12-14 2011-12-13 Ensure Medical, Inc. Apparatus and methods for sealing vascular punctures
US8888812B2 (en) 2000-12-14 2014-11-18 Cordis Corporation Plug with collet and apparatus and methods for delivering such plugs
US8057510B2 (en) 2000-12-14 2011-11-15 Ensure Medical, Inc. Plug with collet and apparatus and method for delivering such plugs
US9655602B2 (en) 2000-12-14 2017-05-23 CARDINAL HEALTH SWITZERLAND 515 GmbH Vascular plug having composite construction
US9492148B2 (en) 2000-12-14 2016-11-15 CARDINAL HEALTH SWITZERLAND 515 GmbH Apparatus and methods for sealing vascular punctures
US6830588B2 (en) 2001-03-08 2004-12-14 Nec Tokin Corporation Artificial sphincter
EP1238638A1 (fr) * 2001-03-08 2002-09-11 Tokin Corporation Sphincter artificiel
WO2002080821A1 (fr) * 2001-04-06 2002-10-17 Core Medical, Inc. Appareil et procedes de fermeture d'ouvertures dans les disques intervertebraux
US10653427B2 (en) 2001-06-27 2020-05-19 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US10624618B2 (en) 2001-06-27 2020-04-21 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US7981139B2 (en) 2002-03-01 2011-07-19 Evalve, Inc Suture anchors and methods of use
US7766926B2 (en) 2002-04-30 2010-08-03 Vance Products Incorporated Sling for supporting tissue
US8070671B2 (en) 2002-07-02 2011-12-06 Torax Medical, Inc. Methods and devices for luminal and sphincter augmentation
EP1517726A4 (fr) * 2002-07-02 2007-04-11 The Foundry Inc Procedes et dispositifs pour le renforcement de lumieres corporelles et des sphincters
EP1517726A2 (fr) * 2002-07-02 2005-03-30 The Foundry, Inc. Procedes et dispositifs pour le renforcement de lumieres corporelles et des sphincters
US8070670B2 (en) 2002-07-02 2011-12-06 Torax Medical, Inc. Methods and devices for luminal and sphincter augmentation
US10667823B2 (en) 2003-05-19 2020-06-02 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US10631871B2 (en) 2003-05-19 2020-04-28 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US10646229B2 (en) 2003-05-19 2020-05-12 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US10828042B2 (en) 2003-05-19 2020-11-10 Evalve, Inc. Fixation devices, systems and methods for engaging tissue
US8579934B2 (en) 2003-10-17 2013-11-12 Ensure Medical, Inc. Locator and delivery device and method of use
US8852229B2 (en) 2003-10-17 2014-10-07 Cordis Corporation Locator and closure device and method of use
US11304715B2 (en) 2004-09-27 2022-04-19 Evalve, Inc. Methods and devices for tissue grasping and assessment
US11484331B2 (en) 2004-09-27 2022-11-01 Evalve, Inc. Methods and devices for tissue grasping and assessment
US8088144B2 (en) 2005-05-04 2012-01-03 Ensure Medical, Inc. Locator and closure device and method of use
US9289198B2 (en) 2005-05-04 2016-03-22 Cordis Corporation Locator and closure device and method of use
US8926654B2 (en) 2005-05-04 2015-01-06 Cordis Corporation Locator and closure device and method of use
US10143461B2 (en) 2005-05-20 2018-12-04 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US10426509B2 (en) 2005-05-20 2019-10-01 Neotract, Inc. Median lobe destruction apparatus and method
US11504149B2 (en) 2005-05-20 2022-11-22 Teleflex Life Sciences Limited Median lobe destruction apparatus and method
EP1887976A2 (fr) * 2005-05-20 2008-02-20 Neotract, Inc. Dispositifs, systemes et procedes de traitement de l'hyperplasie prostatique benigne et d'autres troubles
US11471148B2 (en) 2005-05-20 2022-10-18 Teleflex Life Sciences Limited Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8940001B2 (en) 2005-05-20 2015-01-27 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US10195014B2 (en) 2005-05-20 2019-02-05 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US11090036B2 (en) 2005-05-20 2021-08-17 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10945719B2 (en) 2005-05-20 2021-03-16 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US10925587B2 (en) 2005-05-20 2021-02-23 Neotract, Inc. Anchor delivery system
US10105132B2 (en) 2005-05-20 2018-10-23 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
EP1887976A4 (fr) * 2005-05-20 2012-10-31 Neotract Inc Dispositifs, systemes et procedes de traitement de l'hyperplasie prostatique benigne et d'autres troubles
US10265061B2 (en) 2005-05-20 2019-04-23 Neotract, Inc. Latching anchor device
US10575844B2 (en) 2005-05-20 2020-03-03 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10299780B2 (en) 2005-05-20 2019-05-28 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US10492792B2 (en) 2005-05-20 2019-12-03 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8945152B2 (en) 2005-05-20 2015-02-03 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
US7942806B2 (en) * 2005-12-29 2011-05-17 Ethicon, Inc. Stress urinary incontinence implant and device for deploying same
US10507094B2 (en) * 2006-12-21 2019-12-17 Oz Harmanli Vaginal pessary
US20130025604A1 (en) * 2006-12-21 2013-01-31 Oz Harmanli Vaginal pessary
US10159554B2 (en) 2008-02-18 2018-12-25 Covidien Lp Clip for implant deployment device
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US10182898B2 (en) 2008-02-18 2019-01-22 Covidien Lp Clip for implant deployment device
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9107726B2 (en) 2008-02-18 2015-08-18 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US9005241B2 (en) 2008-02-18 2015-04-14 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US8753359B2 (en) 2008-02-18 2014-06-17 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US10695155B2 (en) 2008-02-18 2020-06-30 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US8814885B2 (en) 2008-03-04 2014-08-26 Cayenne Medical, Inc. Arthroscopic meniscal repair systems and methods
US9724088B2 (en) 2008-03-04 2017-08-08 Cayenne Medical, Inc. Arthroscopic meniscal repair systems and methods
US8888811B2 (en) 2008-10-20 2014-11-18 Covidien Lp Device and method for attaching an implant to biological tissue
US8435253B2 (en) 2008-10-21 2013-05-07 Cayenne Medical, Inc. Meniscal repair systems and methods
US8177795B2 (en) 2008-10-21 2012-05-15 Cayenne Medical, Inc. Meniscal repair systems and methods
US9486208B2 (en) 2009-05-01 2016-11-08 Cayenne Medical, Inc. Meniscal repair systems and methods
US8906045B2 (en) 2009-08-17 2014-12-09 Covidien Lp Articulating patch deployment device and method of use
US9999424B2 (en) 2009-08-17 2018-06-19 Covidien Lp Means and method for reversibly connecting an implant to a deployment device
US10743876B2 (en) 2011-09-13 2020-08-18 Abbott Cardiovascular Systems Inc. System for fixation of leaflets of a heart valve
US10792039B2 (en) 2011-09-13 2020-10-06 Abbott Cardiovascular Systems Inc. Gripper pusher mechanism for tissue apposition systems
US10292801B2 (en) 2012-03-29 2019-05-21 Neotract, Inc. System for delivering anchors for treating incontinence
US10130353B2 (en) 2012-06-29 2018-11-20 Neotract, Inc. Flexible system for delivering an anchor
US11331093B2 (en) 2012-06-29 2022-05-17 Teleflex Life Sciences Limited Flexible system for delivering an anchor
US11850140B2 (en) 2013-03-14 2023-12-26 Teleflex Life Sciences Limited Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10912637B2 (en) 2013-03-14 2021-02-09 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10349932B2 (en) 2013-03-15 2019-07-16 Neotract, Inc. Anchor delivery system
US11129608B2 (en) 2013-03-15 2021-09-28 Neotract, Inc. Anchor delivery system
US11744726B2 (en) 2013-08-01 2023-09-05 Cook Medical Technologies Llc Tissue adjustment implant
US10390943B2 (en) 2014-03-17 2019-08-27 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
US11666433B2 (en) 2014-03-17 2023-06-06 Evalve, Inc. Double orifice device for transcatheter mitral valve replacement
WO2015193890A1 (fr) * 2014-06-16 2015-12-23 Novogi Ltd. Appareil et procédé pour anastomose par compression étagée
US11229435B2 (en) 2014-12-19 2022-01-25 Abbott Cardiovascular Systems Inc. Grasping for tissue repair
US11109863B2 (en) 2014-12-19 2021-09-07 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
US11006956B2 (en) 2014-12-19 2021-05-18 Abbott Cardiovascular Systems Inc. Grasping for tissue repair
US10188392B2 (en) 2014-12-19 2019-01-29 Abbott Cardiovascular Systems, Inc. Grasping for tissue repair
US10893941B2 (en) 2015-04-02 2021-01-19 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
US10376673B2 (en) 2015-06-19 2019-08-13 Evalve, Inc. Catheter guiding system and methods
US10856988B2 (en) 2015-06-29 2020-12-08 Evalve, Inc. Self-aligning radiopaque ring
US10238494B2 (en) 2015-06-29 2019-03-26 Evalve, Inc. Self-aligning radiopaque ring
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
US11096691B2 (en) 2015-07-21 2021-08-24 Evalve, Inc. Tissue grasping devices and related methods
US11759209B2 (en) 2015-07-21 2023-09-19 Evalve, Inc. Tissue grasping devices and related methods
US10413408B2 (en) 2015-08-06 2019-09-17 Evalve, Inc. Delivery catheter systems, methods, and devices
EP3334495A4 (fr) * 2015-08-12 2019-05-01 Innoventions Ltd Système de réparation tissulaire comme la réparation d'un sphincter urinaire et/ou autre, sujet à des fuites
CN108025180A (zh) * 2015-08-12 2018-05-11 英诺威讯有限公司 用于括约肌和其它组织再生的系统
CN108025180B (zh) * 2015-08-12 2022-05-27 英诺威讯有限公司 用于括约肌和其它组织再生的系统
US11109972B2 (en) 2015-10-09 2021-09-07 Evalve, Inc. Delivery catheter handle and methods of use
US10238495B2 (en) 2015-10-09 2019-03-26 Evalve, Inc. Delivery catheter handle and methods of use
US11931263B2 (en) 2015-10-09 2024-03-19 Evalve, Inc. Delivery catheter handle and methods of use
US10736632B2 (en) 2016-07-06 2020-08-11 Evalve, Inc. Methods and devices for valve clip excision
US11653947B2 (en) 2016-10-05 2023-05-23 Evalve, Inc. Cardiac valve cutting device
US11166818B2 (en) 2016-11-09 2021-11-09 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10363138B2 (en) 2016-11-09 2019-07-30 Evalve, Inc. Devices for adjusting the curvature of cardiac valve structures
US10398553B2 (en) 2016-11-11 2019-09-03 Evalve, Inc. Opposing disk device for grasping cardiac valve tissue
US10426616B2 (en) 2016-11-17 2019-10-01 Evalve, Inc. Cardiac implant delivery system
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US11406388B2 (en) 2016-12-13 2022-08-09 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
US10314586B2 (en) 2016-12-13 2019-06-11 Evalve, Inc. Rotatable device and method for fixing tricuspid valve tissue
US11065119B2 (en) 2017-05-12 2021-07-20 Evalve, Inc. Long arm valve repair clip
US11672520B2 (en) 2017-12-23 2023-06-13 Teleflex Life Sciences Limited Expandable tissue engagement apparatus and method
US11298115B2 (en) 2020-08-03 2022-04-12 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions
US11801041B2 (en) 2020-08-03 2023-10-31 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions
US11957358B2 (en) 2020-09-21 2024-04-16 Evalve, Inc. Adjustable arm device for grasping tissues

Also Published As

Publication number Publication date
WO2001026588A3 (fr) 2001-10-11
AU5598300A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
WO2001026588A2 (fr) Methodes non invasives et avec effraction minimale et dispositifs pour le traitement de l'incontinence urinaire ou de l'obstruction urinaire
US10792140B2 (en) Partial cuff
US20040030217A1 (en) Urethral muscle controlled micro-invasive sphincteric closure device
US9084664B2 (en) Method and articles for treatment of stress urinary incontinence
EP2242446B1 (fr) Manchon partiel
US8617046B2 (en) Floating sling for treatment of incontinence
WO2002032321A1 (fr) Dispositif de fermeture sphincterienne micro-invasive commande par les muscles uretraux
JP5001382B2 (ja) 男性尿失禁の治療用具
KR101739304B1 (ko) 최소 침수성 임플란트 조합
US10219808B2 (en) Partial cuff
Leach et al. Modified pereyra bladder neck suspension after previously failed anti-incontinence surgery Surgical technique and results with long-term follow-up
JP2016120323A (ja) 骨盤疾患を治療するための細長い移植片システムおよび方法
WO2013016306A1 (fr) Système d'implant pelvien et procédé
US20090216073A1 (en) Devices and Methods for Placing Slings and Other Materials
AU2016204897B2 (en) Method and articles for treatment of stress urinary incontinence
AU2013201299B2 (en) Method and articles for treatment of stress urinary incontinence
RU2141793C1 (ru) Способ хирургического лечения стресс-недержания мочи у женщин
AU2015202916B2 (en) Minimally invasive implant and method
AU2012287033B2 (en) Pelvic implant system and method
EP2734148A1 (fr) Système d'implant pelvien et procédé
Loughlin Complications of endoscopic bladder neck suspension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP